MiNK Therapeutics will announce its financial results for Q3 2026 on November 11, 2026, and provide updates on its lead iNKT cell therapy, agenT-797, including progress in a Phase 2 trial for acute lung injury. The company will also discuss its collaboration with ARPA-H to develop deployable cell therapies using room-temperature technology and share new data on iNKT therapies for treatment-resistant cancers presented at the SITC 2026 meeting. These developments highlight MiNK's focus on advancing clinical validation and expanding patient access to scalable, off-the-shelf immune therapies. Investors can join a webcast and conference call to learn more about these strategic initiatives and clinical progress.
MiNK Therapeutics' upcoming Q3 2026 results and clinical updates provide context for health sector activity on Pluang. For readers following health stocks, here is Pluang's market snapshot as of Nov 03, 2026 04:11 WIB: out of 150 priced health-sector US stocks, 48 rose and 100 fell. Notable movers include DNA at USD 9.81 with a 12.60% drop and a typical hold time of 9 days, TWST at USD 152.02 down 12.36% with a 27-day hold, and TXG at USD 61.51 down 12.27% with a 92-day hold time.
Global Indemnity Group will postpone its third quarter 2026 earnings call originally scheduled for November 4 to January, when new CEO Jessica Buss will present her vision and priorities for the company. The company will still release its Q3 results ...
Lorraine Ben, former CEO of Lockheed Martin Canada, has joined Syntax Defence to provide expert counsel amid Canada's commitment to invest over half a trillion dollars in defence over the next decade. This includes $180 billion in procurement opportu...
Dianthus Therapeutics, a clinical-stage biotech company, granted stock options to three new non-executive employees as inducements for joining the company. The options cover 26,000 shares at an exercise price of $82.25, vesting over four years. This ...
Zentalis Pharmaceuticals awarded 136,000 non-qualified stock options to four newly hired employees as an inducement to join the company, under Nasdaq Listing Rule 5635(c)(4). The options have an exercise price of $1.85, matching the stock's closing p...
The Federal Home Loan Bank of Atlanta announced the election of three new member directors and the re-election of one independent director to its board for 2026. Suzanne DeFerie was named Chair and Kathy McKinney Vice Chair for 2027, ensuring experie...
